Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Atezolizumab is the first approved PD-L1 inhibitor for patients with advanced non-small cell lung cancer (NSCLC) in Germany. This study aimed to assess effectiveness and safety of this checkpoint inhibitor in clinical routine practice. In addition, potential correlating factors between patient or disease characteristics and clinical benefit of atezolizumab were addressed.
Methods: HYPERION was a prospective, multicenter, non-interventional, two-cohort study collecting primary data in patients with locally-advanced or metastatic NSCLC after prior chemotherapy treated with atezolizumab. Patients were assigned to one of two cohorts depending on their clinical benefit from atezolizumab, i.e., lack of benefit (Cohort 1) or durability of clinical benefit and tumor response (Cohort 2), as assessed by the physicians.
Results: Between May 2018 and August 2023, 353 patients were observed, including 179 in Cohort 1 and 174 in Cohort 2. The median age was 68 years and 61 % were men. The median time to loss of clinical benefit was 106 days (95 % CI: 93, 119) overall (n = 353 patients) and 256 days (95 % CI: 210, 339) for Cohort 2 (n = 174 patients). In total, 243 (68.8 %) patients experienced at least one adverse event (AE) and 146 (41.4 %) patients at least one serious AE. A higher proportion of PD-L1 positive patients was observed for Cohort 2 than for Cohort 1.
Conclusion: HYPERION confirmed effectiveness of atezolizumab in clinical practice. Results supported a known correlation between PD-L1 expression and a higher benefit of atezolizumab treatment. Atezolizumab treatment was associated with an acceptable safety profile.
Micro Abstract: The two-cohort non-interventional study HYPERION assessed the effectiveness and safety of atezolizumab in 353 patients with locally-advanced or metastatic NSCLC after prior chemotherapy, depending on lack of benefit (Cohort 1; n = 179) or durability of clinical benefit and tumor response (Cohort 2; n = 174). Atezolizumab showed effectiveness in clinical practice. Results were consistent with the known safety profile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctarc.2025.100878 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.
Stroke
September 2025
Department of Neurology, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University.
Background: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain.
Methods: CHANCE-2 (Clopidogrel in High-Risk Patients With Acute Non-disabling Cerebrovascular Events-II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles.
Spontaneous Aortic Sealing with Tranexamic Acid in Type A Dissection: A Novel Life-Saving Finding.
Eur J Case Rep Intern Med
August 2025
Department of Gastroenterology and Hepatology, University of Balamand, Beirut, Lebanon.
Unlabelled: Aortic dissection is a life-threatening cardiovascular emergency, particularly Stanford type A, which typically necessitates urgent surgical intervention. Despite advances in surgical techniques and perioperative care, preoperative bleeding and coagulopathy remain significant challenges. Tranexamic acid, an antifibrinolytic agent, is widely used to minimize perioperative bleeding in cardiovascular surgeries; however, its role in the non-surgical, preoperative stabilization of aortic dissection has not been well established.
View Article and Find Full Text PDFWhen Skin Reactions Interrupt Bone Therapy: Severe Cutaneous Adverse Reaction to Romosozumab Leading to Treatment Discontinuation.
Eur J Case Rep Intern Med
August 2025
General medicine department, Universidad de Cartagena, Cartagena, Colombia.
Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.
Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.
Background: Acupuncture is a widely recognized complementary therapy with proven therapeutic benefits; however, concerns regarding patient safety persist due to adverse events ranging from minor complications to severe outcomes like pneumothorax and nerve injury.
Objective: This study aims to identify common adverse events in acupuncture, propose innovative risk mitigation strategies, establish standardized best practices, enhance practitioner training, and examine global disparities in safety protocols.
Design: Comprehensive review of existing literature, clinical case studies, and international safety guidelines.
Acupuncture Safety in Diabetic Limb: A Scoping Review.
Med Acupunct
August 2025
Acupuncture Service, Pain Management Centre, Sengkang General Hospital, Singapore, Singapore.
Background: Any injury to the diabetic limbs may portent disastrous consequences. However, it is not uncommon for diabetics to also seek complementary and alternative medicine for treatment, such as acupuncture. There are limited data on infective or ulcerative adverse events regarding acupuncture in diabetic limbs.
View Article and Find Full Text PDF